There were 1,520 press releases posted in the last 24 hours and 401,107 in the last 365 days.
Opinion/decision on a Paediatric investigation plan (PIP): Spevigo, Spesolimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Dermatology, PIP number: P/0247/2023
P/0247/2023 : EMA decision of 14 July 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral for spesolimab (Spevigo), (EMEA-002475-PIP03-22)